DAM
KALV

DLD Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

DLD Asset Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-50,000
Closed -$891K – 93
2019
Q4 		$891K Buy
+50,000
New +$653K 0.05% 78

Other funds holding KALV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

DLD Asset Management's KALV Position: Q1 2020 in Review

DLD Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2020, closing a stake of 50,000 shares — an estimated $891K sold.

DLD Asset Management first reported a position in KALV in Q4 2019 and held it in 1 quarter. The position peaked at $891K in Q4 2019. 69 funds tracked by Wall St. Rank hold KALV as of Q1 2020.

  • DLD Asset Management reported no remaining KalVista Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • DLD Asset Management sold 50,000 KalVista Pharmaceuticals shares in Q1 2020, an estimated $891K.
  • DLD Asset Management first reported a position in KalVista Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • DLD Asset Management's KalVista Pharmaceuticals position peaked at $891K in Q4 2019.
  • 69 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2020.

Based on DLD Asset Management's 13F filing for Q1 2020, filed 14 May 2020.